Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Name: Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
License: Public Domain

Merck Sharp & Dohme LLC

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

metastatic non-small cell lung cancer

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 208463
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.